Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Journal Year:
2024,
Volume and Issue:
136, P. 111228 - 111228
Published: Dec. 22, 2024
Postoperative
cognitive
dysfunction
(POCD)
is
characterized
by
a
decline
in
functions,
including
memory,
attention,
and
executive
abilities,
following
surgery,
with
no
effective
therapeutic
drugs
currently
available.
Arketamine,
the
(R)-enantiomer
of
ketamine,
has
shown
promise
mitigating
deficits
animal
models.
In
this
study,
we
investigated
whether
arketamine
could
ameliorate
mouse
model
POCD,
focus
on
role
transforming
growth
factor
(TGF)-β1
its
effects.
POCD
mice
displayed
impairments
demyelination
corpus
callosum.
A
single
injection
(10
mg/kg)
significantly
improved
both
function
callosum
mice.
Notably,
pretreatment
RepSox
mg/kg),
TGF-β
receptor
1
inhibitor,
blocked
beneficial
effects
demyelination.
Moreover,
intranasal
administration
TGF-β1
(3.0
μg/kg)
markedly
alleviated
These
findings
suggest
that
exerts
through
TGF-β1-dependent
mechanism,
positioning
it
as
potential
option
for
POCD.
European Journal of Pharmacology,
Journal Year:
2024,
Volume and Issue:
985, P. 177096 - 177096
Published: Nov. 3, 2024
The
novel
antidepressant
arketamine,
the
(R)-enantiomer
of
ketamine,
has
been
shown
to
ameliorate
demyelination
and
facilitate
remyelination
in
brains
cuprizone
(CPZ)-treated
mice.
However,
mechanisms
behind
its
effects
remain
unclear.
Given
role
transforming
growth
factor
β1
(TGF-β1)
arketamine's
antidepressant-like
effects,
we
examined
whether
TGF-β1
also
plays
a
on
CPZ-treated
Additionally,
investigated
intranasal
these
Repeated
intermittent
administration
arketamine
(10
mg/kg/day,
twice
weekly
for
last
2-weeks)
attenuated
corpus
callosum
(CC)
CPZ
(6
weeks)-treated
Furthermore,
pretreatment
with
RepSox
mg/kg/day),
an
inhibitor
TGF-β
receptor
1,
significantly
blocked
beneficial
CC
repeated
(3.0
μg/kg/day,
2
weeks)
ameliorated
facilitated
These
data
suggest
that
can
mitigate
facilitates
mice
through
TGF-β1-dependent
mechanism.
Journal of Psychopharmacology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 24, 2025
Background:
Low-dose
ketamine
is
an
N-methyl-D-aspartate
receptor
antagonist
that
exerts
antidepressant
effect
on
patients
with
treatment-resistant
depression
(TRD).
This
may
extend
beyond
the
glutamatergic
hypothesis.
Nevertheless,
roles
of
genes
encoding
other
monoamine
neurotransmitters
(i.e.,
serotonin
and
dopamine)
in
neuromechanism
low-dose
remain
unknown.
Methods:
In
this
clinical
trial,
which
involved
65
TRD,
21
received
0.5
mg/kg
ketamine,
20
0.2
24
normal
saline.
All
were
genotyped
for
684,616
single-nucleotide
polymorphisms
(SNPs).
A
total
50
neurotransmitter-related
candidate
genes,
including
HTR2A
HTR2C
from
serotoninergic
system,
CHRM4
CHRNB1
cholinergic
DRD2
dopaminergic
selected
to
conduct
a
gene-based
genome-wide
association
study
effects
ketamine.
Results:
Gene-set
enrichment
analysis
revealed
pathway
underlying
neuroactive
ligand–receptor
interaction
(KEGG)
played
pivotal
role
biomechanisms
ketamine’s
effect.
Specifically,
SNPs
related
system
(e.g.,
rs2644247
CHRM5),
μ1
opioid
rs2473546
OPRM1),
rs2617577
SLC6A3),
serotonergic
(HTR2A),
cannabinoid
(CNR2),
σ1
(SIGMAR1)
associated
Discussion:
has
effect,
be
multiple
neurotransmitter
systems
receptor.
The Journal of Maternal-Fetal & Neonatal Medicine,
Journal Year:
2024,
Volume and Issue:
37(1)
Published: Jan. 2, 2024
This
study
investigates
the
effects
of
administering
intravenous
esketamine
at
a
dose
0.25
mg/kg
to
pregnant
patients
receiving
epidural
anesthesia
for
emergency
cesarean
section
on
both
maternal
and
neonatal
outcomes.
Translational Psychiatry,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Nov. 9, 2024
Acute
kidney
injury
(AKI)
is
a
serious
condition
characterized
by
decreased
urine
output,
often
accompanied
psychiatric
symptoms
like
depression.
However,
there
are
limited
pharmacological
treatments
available
for
AKI
and
its
associated
depressive
symptoms.
In
this
study,
we
investigated
whether
cisplatin-induced
in
mice
leads
to
depression-like
behaviors
ketamine
could
alleviate
both
the
these
behaviors.
Mice
with
exhibited
elevated
levels
of
creatinine
urea,
damage,
increased
molecule-1
protein,
pathological
changes
liver,
colon,
spleen.
They
also
showed
reduced
expression
synaptic
proteins
prefrontal
cortex.
Remarkably,
single
dose
significantly
changes.
Interestingly,
beneficial
effects
on
kidneys,
other
organs,
behaviors,
were
reversed
tropomyosin
receptor
kinase
B
(TrkB)
inhibitor
ANA-12.
Western
blot
analysis
revealed
involvement
TrkB
ERK
(extracellular
signal-regulated
kinase)-CREB
(cAMP
response
element
binding
protein)
signaling
pathway.
Additionally,
metabolomics
indicated
that
blood
metabolites,
such
as
C16-ceramide,
may
contribute
model.
These
findings
suggest
nephrotoxicity
contributes
can
damage
modulating
ERK-CREB
pathways,
well
altering
metabolites.
role
kidney-brain
axis
remains
unclear.
Furthermore,
have
therapeutic
potential
treating
diseases
AKI,
along
Journal of Anesthesia and Translational Medicine,
Journal Year:
2024,
Volume and Issue:
3(4), P. 155 - 165
Published: Nov. 29, 2024
Depression
and
pain
are
common
comorbidities
in
cancer
patients,
ketamine,
a
dissociative
anesthetic,
has
shown
potential
managing
both.
This
review
summarizes
current
literature
on
ketamine
its
enantiomer,
esketamine,
depression
the
oncologic
population.
Studies
indicate
that
sub-anesthetic
doses
of
intravenous
esketamine
can
alleviate
postoperative
depressive
symptoms
patients
with
tolerable
safety
profile.
Research
into
non-intravenous
routes
for
management
population
remains
limited.
Ketamine
also
proven
effective
acute
pain,
particularly
through
administration.
While
alternative
administration
routes,
such
as
local
infiltration
intramuscular
methods,
show
mixed
results,
they
may
provide
viable
options
averse
to
(IV).
However,
effectiveness
chronic
inconsistent.
Overall,
offers
promising
approach
patients.
